PTC Therapeutics, INC.: directors' dealings · United States · SEC (Form 4)

About PTC Therapeutics, INC.

PTC Therapeutics, Inc. (NASDAQ: PTCT) is a U.S.-listed biopharmaceutical company headquartered in Warren, New Jersey, United States. For international investors, PTC is best understood as a rare-disease specialist with a commercial and R&D franchise focused on neurology and metabolic disorders. The company was founded in the late 1990s; SEC records show a name change date of 1998, consistent with its long operating history in rare-disease drug development. Over time, PTC has built a portfolio designed around high-unmet-need indications, where clinical differentiation and regulatory execution can be more important than broad primary-care scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai)) PTC’s current investment case is driven by a combination of marketed products and a diversified pipeline. Its commercial portfolio has historically included Emflaza (deflazacort) and Translarna (ataluren), both important in the rare-disease space, although those franchises have faced headwinds from generic competition in Emflaza and adverse regulatory developments in Europe for Translarna. More recently, the company has expanded its growth platform with Sephience (sepiapterin) for phenylketonuria, or PKU. Sephience received key approvals in 2025 in the United States, the European Economic Area, and Japan, followed by approval in Brazil in February 2026. PTC also markets Upstaza/Kebilidi in certain geographies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai)) From a competitive perspective, PTC occupies a niche position among rare-disease biopharma peers: it is neither a large diversified pharma company nor a pure early-stage research story. Instead, it combines commercial execution with deal-making and royalty monetization. A major recent event was the December 2025 sale of the remainder of its Evrysdi royalty stream to Royalty Pharma, while retaining certain milestone rights tied to Roche sales performance. Another key milestone was the Novartis collaboration on votoplam for Huntington’s disease, which drove a large amount of collaboration and license revenue in 2025 and added strategic optionality to the pipeline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm)) Geographically, PTC has a global footprint across North America, Europe, and parts of Asia, and management has indicated that Sephience could expand to 20 to 30 countries by the end of 2026. The company’s principal executive offices are in Warren, New Jersey, and its public filings and corporate communications confirm its U.S. listing on the NASDAQ market. For investors, PTC offers exposure to rare-disease commercialization, regulatory catalysts, and launch execution, but also carries typical biotech risks tied to reimbursement, competition, and trial outcomes. Recent financial updates show meaningful product-revenue momentum from Sephience, even as legacy products remain under pressure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm))